Immuron Ltd has released a press release.
Immuron Reports Results in SAH Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Underwritten Public Offer
- Immuron Prices Underwritten Public Offering of ADSs
- Proposed Public Offer of IMRN ADSs
- Immuron North American revenue surges by 52% in FY19
- US DoD Reports Results from Travelan Shigellosis Study
Later from Immuron
- Appendix 4E & Annual Report to shareholders
- US Defense Reports Immuron Travelan Targets Cholera
- US Defense funds AU$5.5M for Immuron New Gastro Weapon
- Immuron North American Q1 Sales Up 111% YoY
- Immuron Receives AUD $0.53M R&D Tax Concession Refund
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron